Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Efficacy and Safety of ALIC/NAcc-DBS for Treatment-refractory OCD

NCT: NCT04967560 · COMPLETED

NCT IDNCT04967560
StatusCOMPLETED
Start Date2021-07-30
Completion2024-01-29
SponsorShanghai Mental Health Center (OTHER)
First posted
Last updated

Brief Summary

The present study aims to explore the efficacy and safety of DBS targeted the combination of the anterior limb of internal capsule and nucleus accumbens (ALIC/NAcc-DBS) to refractory OCD, based on multicenter, randomized, double-blinded, sham-stimulation controlled design, that could help to obtain stronger evidence of the efficacy of multiple targets.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑